Brief: Olema Oncology Announces New Clinical Data For Palazestrant In Combination With Ribociclib To Be Presented At The 2024 Esmo Breast Cancer Annual Congress
08/05/2024 12:19
May 8 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL DATA FOR
PALAZESTRANT IN
COMBINATION WITH RIBOCICLIB TO BE PRESENTED AT THE 2024 ESMO
BREAST CANCER ANNUAL CONGRESS
Source text for Eikon: ID:nGNX9TxyYF
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Oncology
See all newsBrief: Olema Pharmaceuticals Changes Corporate Name To Olema Oncology, Effective Today
Olema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary
Olema Pharma Q3 net loss widens on higher costs
Brief: Olema Pharmaceuticals Q3 Net Income USD -73.599 Million
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary